| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd, Jushi Biopharmaceutical Co Ltd | Carcinoma, Transitional Cell; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | 詳細 |
| SHR-A2102 | SHR-A2102 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Bulumtatug fuvedotin | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma; Carcinoma, Transitional Cell; Genital Neoplasms, Female; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| Zelenectide pevedotin | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Neoplasms; Solid tumours | 詳細 |
| VBC-103 | AVZO-103; VAC-103; VBC-103; VBC103 | Phase 2 Clinical | VelaVigo Cayman Ltd | Carcinoma; Carcinoma, Transitional Cell; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| SC-101 | SC-101 | Phase 2 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Breast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 詳細 |
| SKB-410 | SKB410; SKB-410; MK-3120 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Neoplasms; Solid tumours; Urinary Bladder Neoplasms | 詳細 |
| PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells | Phase 1 Clinical | Shenzhen Misheng Biotechnology Co Ltd | Prostatic Neoplasms; Solid tumours | 詳細 | |
| BA-3361 | BA3361; BA-3361 | Phase 1 Clinical | Bioatla | Neoplasms | 詳細 |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| EB-DT-NK-UC101 | EB-DT-NK-UC101 | Phase 1 Clinical | Beijing Biotech | Carcinoma; Carcinoma, Transitional Cell; Urethral Neoplasms; Urinary Bladder Neoplasms | 詳細 |
| 68Ga-Nectin-4 | Phase 1 Clinical | The First Affiliated Hospital Of Soochow University | Solid tumours | 詳細 | |
| [64Cu]Cu-AKY-1189 | [64Cu]Cu-AKY-1189 | Phase 1 Clinical | Aktis Oncology Inc | Neoplasms | 詳細 |
| AKY-1189 | AKY-1189; [225Ac]Ac-AKY-1189; 225Ac-AKY-1189 | Phase 1 Clinical | Aktis Oncology Inc | Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| AK-146-D-1 | AK146D1; AK-146-D1 | Phase 1 Clinical | Solid tumours | 詳細 | |
| Nectin-4 targeting antibody drug conjugate 2 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | 詳細 | |
| Nectin-4 targeting antibody drug conjugate 1 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | 詳細 | |
| XKDCT-293 | XKDCT-293; XKDCT293 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | 詳細 |
| IPH-4502 | IPH4502; IPH-4502 | Phase 1 Clinical | Innate Pharma SA | Solid tumours | 詳細 |
| LY-4052031 | LY-4052031 | Phase 1 Clinical | Eli Lilly & Company Lilly France | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Pelvic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| RNDO-564 | RNDO-564 | Phase 1 Clinical | Rondo Therapeutics | Carcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Carcinoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 詳細 |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | 詳細 |
| Nectin-4 targeting radiopharmaceutical program (Aktis Oncology) | Clinical | Aktis Oncology Inc | Solid tumours | 詳細 | |
| [68Ga]Ga-NOTA-RND20 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| [18F]F-RESCA-RND20 | Clinical | Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Digestive System Neoplasms | 詳細 | |
| CT-341 | CT-341 | Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | 詳細 |
| 68Ga-N188 | 68Ga-N188; 68-Ga-N-188 | Clinical | Yunnan Baiyao Group Co Ltd | Carcinoma, Transitional Cell; Neoplasms | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | AGS-22C3E; AGS-22C3; ASG-22CE; AGS-M6; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22M6E | Approved | Agensys Inc, Seagen Inc | Padcev, 备思复 | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Carcinoma; Carcinoma in Situ; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 詳細 |

